SCHEMBL4846728

SCHEMBL4846728

CCOC(=O)c1cn(Cc2ccccc2)nc1OCc1ccc(OCc2nc(-c3ccco3)oc2C)c(OCc2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.43
KDM4E B2RXH2 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
TSHR P16473 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 3/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
ADORA3 P0DMS8 10/20 0.39
ADORA2A P29274 10/20 0.39
ADORA1 P30542 9/20 0.39
ADORA2B P29275 5/20 0.39
LMNA P02545 4/20 0.39
USP2 O75604 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 2/20 0.38
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852926 0.98 PPARG (0.43) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4847886 0.96 PPARG (0.48) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4848061 0.96 PPARG (0.43) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4854332 0.96 PPARG (0.45) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4853530 0.95 PPARG (0.40) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4848634 0.94 PPARG (0.39) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4845680 0.94 PPARG (0.39) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4847085 0.94 PPARG (0.39) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4845327 0.94 PPARG (0.39) PPARGKDM4ESMN1; SMN2TSHRALDH1A1
SCHEMBL4851674 0.93 PPARG (0.46) PPARGKDM4ESMN1; SMN2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885KDM4E 719/4885SMN1; SMN2 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.